Neoantigen Vaccines for Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 August 2026 | Viewed by 8
Special Issue Editor
Special Issue Information
Dear Colleagues,
Neoantigens are tumor-specific antigens that evade central immune tolerance mechanisms, making them ideal targets for cancer vaccine therapy. Within the body, the presentation of neoantigens to T cells by dendritic cells is critically important in immune priming, which activates and expands neoantigen-reactive T cells. The research into the application of neoantigens in cancer vaccines is rapidly advancing, with some vaccine types—such as mRNA-based neoantigen vaccines—already having been approved by the FDA. Beyond mRNA-based vaccines, other types of neoantigen vaccine under development include DNA-based, peptide-based, and dendritic cell-based vaccines (where the respective antigens are loaded onto dendritic cells). Among these, dendritic cell-based vaccines have undergone numerous clinical trials over the years, and their safety has been established. Vaccines where neoantigen peptides are loaded onto dendritic cells show high potential compared to traditional shared-antigen peptides.
The application of each different vaccine entails numerous practical clinical considerations beyond efficacy and adverse events, including cost, lead time, and logistical complexity.
Furthermore, adoptive immunotherapy using neoantigen-specific T cells—where T cells targeting neoantigens are activated and expanded ex vivo before being administered to patients—represents another future therapeutic option.
Therefore, for this Special Issue, we welcome research papers discussing therapeutic applications of neoantigens, such as those described above.
Dr. Takashi Morisaki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neoantigens
- vaccine
- dendritic cells
- cancer
- immunotherapy
- priming
- CTL
- helper T cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
